TOVX
Theriva Biologics, Inc.Company Information
- Company Name
- Theriva Biologics, Inc.
- CIK
- CIK0000894158
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- TOVX: NYSE
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- TOVX
SEC filing data through
Insider Sentiment
- Last purchase
- 2023-06-07
- Last sale
- —
- Shares purchased (TTM)
- 240,000
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 1,893,324
- Shares outstanding
- 45,892,668
- Ownership
- 4.13%
Earnings Market Reaction
- Filing date
- 2026-08-11
- Price on filing date
- —
- 1-month reaction
- 8.70%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 11 | 14 | 13 | 8 | 12 | 10 | 12 | 16 | 17 | 18 | 23 | 31 | ||||||
| Grants Receivable Current | 2 | 2 | 3 | 2 | 2 | 2 | 3 | 2 | 2 | 2 | 2 | 1 | ||||||
| Prepaid Expense And Other Assets Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | ||||||
| Assets Current | 14 | 17 | 17 | 10 | 15 | 12 | 16 | 20 | 20 | 22 | 27 | 35 | ||||||
Assets Noncurrent | ||||||||||||||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Restricted Cash Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Right Of Use Asset | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | ||||||
| Intangible Assets Net Excluding Goodwill | 19 | 19 | 20 | 20 | 20 | 18 | 17 | 19 | 19 | 19 | 20 | 19 | ||||||
| Assets | 35 | 38 | 38 | 31 | 36 | 32 | 35 | 40 | 42 | 49 | 55 | 62 | ||||||
Liabilities Current | ||||||||||||||||||
| Goodwill | - | - | - | - | - | - | 0 | - | 1 | 6 | 6 | 5 | ||||||
| Accounts Payable Current | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Accrued Liabilities Current | 6 | 6 | 6 | 8 | 9 | 4 | 3 | 4 | 3 | 3 | 3 | 6 | ||||||
| Business Combination Contingent Consideration Liability Current | 3 | 1 | - | - | - | 1 | - | - | - | - | - | - | ||||||
| Employee Related Liabilities Current | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | ||||||
| Contract With Customer Liability Current | - | - | - | - | - | - | - | - | - | - | 1 | 1 | ||||||
| Loans Payable Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Liability Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | ||||||
| Liabilities Current | 12 | 10 | 10 | 11 | 12 | 8 | 8 | 7 | 7 | 6 | 7 | 9 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Business Combination Contingent Consideration Liability Noncurrent | 7 | 9 | 10 | 11 | 10 | 6 | 7 | 7 | 6 | 6 | 6 | 6 | ||||||
| Long Term Loans Payable | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Deferred Income Tax Liabilities Net | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Operating Lease Liability Noncurrent | 1 | 2 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | ||||||
| Liabilities | 23 | 23 | 23 | 24 | 25 | 17 | 16 | 15 | 15 | 15 | 16 | 18 | ||||||
| Contract With Customer Liability Noncurrent | - | - | - | - | - | - | - | - | - | - | 1 | 1 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 376 | 376 | 374 | 363 | 362 | 356 | 356 | 355 | 350 | 347 | 347 | 346 | ||||||
| Treasury Stock Value | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 0 | 0 | 1 | 1 | 1 | -1 | -1 | 0 | -1 | -1 | 0 | -1 | ||||||
Temporary Equity | ||||||||||||||||||
| Retained Earnings Accumulated Deficit | -364 | -361 | -359 | -357 | -352 | -339 | -335 | -331 | -323 | -314 | -309 | -304 | ||||||
| Stockholders Equity | 12 | 15 | 15 | 7 | 11 | 15 | 19 | 25 | 26 | 31 | 37 | 41 | ||||||
| Liabilities And Stockholders Equity | 35 | 38 | 38 | 31 | 36 | 32 | 35 | 40 | 42 | 49 | 55 | 62 | ||||||
| Preferred Stock Shares Authorized | - | - | - | 10 | 10 | 10 | - | - | - | - | - | - | ||||||
| Preferred Stock Shares Issued | - | - | - | 0 | 0 | 0 | - | - | - | - | - | - | ||||||
| Preferred Stock Shares Outstanding | - | - | - | 0 | 0 | 0 | - | - | - | - | - | - | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 350 | 350 | 350 | 350 | 350 | 350 | 350 | 350 | 350 | 350 | 350 | 350 | ||||||
| Common Stock Shares Issued | 46 | 46 | 36 | 10 | 9 | 3 | 3 | 3 | 1 | 1 | 1 | 1 | ||||||
| Shares Outstanding | 46 | 46 | 36 | 10 | 9 | 3 | 3 | 25 | 1 | 1 | 1 | 1 | ||||||
| Treasury Stock Common Shares | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | ||||||
| Series C Convertible Preferred Stock | - | - | - | - | - | - | 0 | -0 | 0 | 0 | 0 | 0 | ||||||
| Series D Convertible Preferred Stock | - | - | - | - | - | - | 0 | -0 | 0 | 0 | 0 | 0 | ||||||
| Temporary Equity Shares Authorized | - | - | - | - | - | - | 10 | 10 | 10 | 10 | 10 | - | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialTheriva Biologics, Inc. (TOVX) — SEC Financial Statements & Analysis
Theriva Biologics, Inc. (TOVX) is a pharmaceutical preparations company, incorporated in NV. Theriva Biologics, Inc. trades on NYSE as: TOVX. Theriva Biologics, Inc. (TOVX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11. Based on that filing, Theriva Biologics, Inc. carries a market cap of $11.47M, a P/E ratio of -0.87x, a P/B ratio of 0.94x, a P/S ratio of 19.12x, an enterprise value of $170.17K, and an EV/EBITDA multiple of -0.01x. On profitability, it posts an operating margin of -1987.33%, a net margin of -2188.00%, a Return on Equity (ROE) of -115.11%, a Return on Assets (ROA) of -37.14%, and a Return on Invested Capital (ROIC) of -680.24%. Per share, it reports EPS of $-0.29, diluted EPS of $-0.29, free cash flow per share of $-0.28, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of -55.58% year-over-year and EPS growth of -93.46% year-over-year. On the balance sheet, it maintains a current ratio of 1.13x, a quick ratio of 1.07x, working capital of $1.56M, a debt-to-equity ratio of 1.86x, a debt ratio of 0.65, free cash flow of $-12.76M (TTM), and net debt of $-11.30M. Figures sourced from SEC EDGAR.
- Market Cap
- $11.47M
- P/E TTM
- -0.87x
- EPS TTM
- $-0.29
- P/B TTM
- 0.94x
- ROE TTM
- -115.11%
- ROA TTM
- -37.14%
- Debt To Equity
- 1.86x
- Free Cash Flow TTM
- $-12.76M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Theriva Biologics, Inc. in?
Theriva Biologics, Inc. (TOVX) operates in the Pharmaceutical Preparations industry.
What exchange does TOVX trade on?
Theriva Biologics, Inc. (TOVX) trades on the NYSE.
Where is Theriva Biologics, Inc. incorporated?
Theriva Biologics, Inc. is incorporated in NV.
When was Theriva Biologics, Inc. (TOVX)'s most recent SEC filing?
Theriva Biologics, Inc. (TOVX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11.
What is TOVX's market cap?
Theriva Biologics, Inc. (TOVX) has a market capitalization of $11.47M as of 2026-06-30.
What is TOVX's EPS (earnings per share)?
Theriva Biologics, Inc. (TOVX)'s trailing twelve month EPS is $-0.29 as of 2026-06-30.
What is TOVX's ROE (return on equity)?
Theriva Biologics, Inc. (TOVX)'s trailing twelve month Return on Equity (ROE) is -115.11% as of 2026-06-30.
What is TOVX's ROA (return on assets)?
Theriva Biologics, Inc. (TOVX)'s trailing twelve month Return on Assets (ROA) is -37.14% as of 2026-06-30.
What is TOVX's ROIC (return on invested capital)?
Theriva Biologics, Inc. (TOVX)'s trailing twelve month Return on Invested Capital (ROIC) is -680.24% as of 2026-03-31.
What is TOVX's EV/EBITDA?
Theriva Biologics, Inc. (TOVX)'s trailing twelve month EV/EBITDA is -0.01x as of 2026-06-30.